Clinical trials: Aggressive Behavior, open to volunteers
Diffuse Large B-Cell Lymphoma (DLBCL)
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten…
- Trial name
- NCT07887750
- Testing
- REGN9220, Odronextamab
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Oral Cancer
Clinical and Molecular Features of Oral Premalignancy and Oral Cancer
Investigators will employ serial assessments of tissue biopsy and additional biomarkers that reflect burden of disease and predict treatment response.
- Trial name
- NCT06550050
- Testing
- Radiation
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT07097363
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Aggressive NK Cell Leukemia
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.
- Trial name
- NCT05863234
- Testing
- PPMX-T003
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Hiroshima University Hospital
Adenoid Cystic Carcinoma
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Phase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.
- Trial name
- NCT07162480
- Testing
- P-Sam
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or…
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Trial name
- NCT05475925
- Testing
- DR-01
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Dren Bio
Depression, Anxiety
Efficacy of a Multi-level School Intervention for LGBTQ Youth
Efficacy of a Multi-level School Intervention for LGBTQ Youth
- Conditions
- Depression, Anxiety, Post Traumatic Stress Disorder, Coping Behavior
- Trial name
- NCT05541406
- Testing
- Proud & Empowered, Control Group
- Where
- 23 sites in United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Bullying, Cyberbullying
Using Digital Health Technology to Prevent Bullying and Cyberbullying Among Elementary School Students
This project is designed to address the urgent need for an effective primary prevention approach to the problem of bullying and cyberbullying among elementary school students.
- Conditions
- Bullying, Cyberbullying, Smoking
- Trial name
- NCT06592872
- Testing
- Bullying prevention
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Prostate Cancer
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
- Trial name
- NCT06085729
- Testing
- ADI-PEG 20, Cabazitaxel, Carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Post-ERCP Pancreatitis, Pancreatitis
Short-Stay Aggressive Hydration to Prevent Post-ERCP Pancreatitis
Post-ERCP pancreatitis (PEP) is the most common serious adverse event after endoscopic retrograde cholangiopancreatography (ERCP), occurring in roughly 7-15% of patients.
- Trial name
- PuSH (NCT07776561)
- Testing
- Short-Stay Aggressive Hydration, Standard Peri-procedural Hydration, Rectal Indomethacin
- Where
- Australia
- Volunteers
- 1,300 people
- Sponsor
- Westmead Hospital
Emotion Regulation Difficulties; Risky Behaviors (Substance Use, Risky Sexual Behavior, Self-harm, Aggression, Disordered Eating)
The Effects of the PsyPills App on Emotion Regulation and Risk Behaviors in Emerging Adults: A Randomized Clinical Trial
This study aims to investigate the effects of the PsyPills mobile application on improving emotion regulation and reducing risk behaviors among emerging adults.
- Trial name
- NCT07304830
- Testing
- PsyPills, MoodWheel
- Where
- Romania
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Babes-Bolyai University
Relapsed or Refractory Aggressive B-cell Lymphoma
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
This study consists of two sequential treatment phases. In the first phase, patients with r/r aggressive B-NHL receive two cycles of glofitamab ± investigator-selected agents.
- Trial name
- NCT06996132
- Testing
- Glofitamab, Chimeric Antigen Receptor T Cells (CAR-T)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China